BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15867251)

  • 21. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
    Szatmári T; Huszty G; Désaknai S; Spasokoukotskaja T; Sasvári-Székely M; Staub M; Esik O; Sáfrány G; Lumniczky K
    Cancer Gene Ther; 2008 Mar; 15(3):154-64. PubMed ID: 18188186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
    Chen H; Wei W; Guo Y; Liu A; Tong H; Wang Z; Tan W; Liu J; Lin S
    Oncol Rep; 2011 May; 25(5):1253-61. PubMed ID: 21305255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
    Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
    Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
    Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
    Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
    Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forced expression of cytidine deaminase confers sensitivity to capecitabine.
    Morita T; Matsuzaki A; Kurokawa S; Tokue A
    Oncology; 2003; 65(3):267-74. PubMed ID: 14657601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
    Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
    PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

  • 34. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
    Céspedes MV; Guillén MJ; López-Casas PP; Sarno F; Gallardo A; Álamo P; Cuevas C; Hidalgo M; Galmarini CM; Allavena P; Avilés P; Mangues R
    Dis Model Mech; 2016 Dec; 9(12):1461-1471. PubMed ID: 27780828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOBEC3 upregulation drives gemcitabine resistance.
    Maciejowski J; Mohamed T
    Nat Cancer; 2024 Jun; 5(6):818-820. PubMed ID: 38778178
    [No Abstract]   [Full Text] [Related]  

  • 37. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
    de Ruijter AJ; Leen R; Hoebink J; Caron HN; van Kuilenburg AB
    Cancer Lett; 2006 Feb; 233(2):240-6. PubMed ID: 15907366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
    Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H
    Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
    Miwa M; Eda H; Ura M; Ouchi KF; Keith DD; Foley LH; Ishitsuka H
    Clin Cancer Res; 1998 Feb; 4(2):493-7. PubMed ID: 9516941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.